Table 4. Effect of IPTc on clinical malaria during the intervention period.

	Study Site	Drug Regimen	No. of children	Definition of clinical malaria (fever or history of fever plus any level of parasitaemia)
				No. of episodesA	Incidence Rate per 1000 PYAR	Rate Difference per 1000 PYAR	PE (95% CI)
Cisse (2006) [20]	Niakhar	SP+AS	542	96	758	3681	83 (79–86)
		Placebo	546	438	4439		-
Kweku (2008) [22]	Hohoe	SP bimonthly	613	112	403	214	35 (17–48)
		AS+AQ bimonthly	562	109	425	192	31 (13–46)
		AS+AQ monthly	626	44	153	464	75 (65–82)
		Placebo	650	183	617		-
Dicko (2008) [21]	Kambila	SP bimonthly	58	30	2000	4544	69 (54–80)
		Control	59	86	6544		-
Bojang (2010) [19]	Basse	SP+AQ	336	4	58	733	93 (79–97)
		SP+PQ	336	4	57	734	93 (80–97)
		DHA+PQ	336	7	103	688	87 (71–94)
		Control	286	41	791		-
Dicko (2011) [12]	Kati Region	SP+AQ	1509	149	411	1996	83 (80–86)
		Placebo	1508	832	2407		-
Konaté (2011) [13]	Boussé	SP+AQ	1509	416	1114	2671	71 (67–74)
		Placebo	1505	1232	3785		-
Sesay (2011) [23]	Farafenni	SP+AQ	639	1	5	6	49 (−459–95)
		Placebo	638	2	11

^ATotal number of clinical malaria episodes, AQ: amodiaquine, AS: artesunate, CI: confidence interval, DHA: dihydroartemisinin, PE: protective efficacy, PQ: piperaquine, PYAR: person years at risk, SP: sulphadoxine pyrimethamine.